Financial Engines Advisors L.L.C. Reduces $572K in Abbott Laboratories ($ABT)

Financial Engines Advisors L.L.C. has reduced its position in Abbott Laboratories (NYSE: ABT) by 21.6%, according to its latest 13F filing with the SEC. The firm sold 6,453 shares during the period, leaving it with 23,405 shares valued at about $2.1 million.

What Changed in Financial Engines Advisors' Abbott Laboratories Position

Financial Engines Advisors trimmed its holdings in Abbott Laboratories, moving from 29,858 shares to 23,405 shares. The reduction of 6,453 shares represents a 21.6% decrease, as per the filing reflecting holdings at the end of the quarter.

Other Institutional Activity in Abbott Laboratories

Several other major institutional investors have also adjusted their positions in Abbott Laboratories. BlackRock, Inc. reduced its holdings by 1,221,310 shares, ending with 145,687,458 shares valued at approximately $14.96 billion. Capital Research Global Investors increased its stake significantly by 10,606,123 shares, bringing its total to 49,775,362 shares worth about $5.11 billion. Meanwhile, Charles Schwab Investment Management Inc. saw a dramatic increase, adding 32,310,527 shares to hold 45,500,055 shares valued at around $4.67 billion.

Abbott Laboratories Stock Up 0.1%

Shares of Abbott Laboratories are currently trading at $89.77. The company, with a market cap of about $157.8 billion, has a P/E ratio of 25.38 and a forward P/E of 14.96. Abbott's stock has ranged between $81.97 and $139.06 over the past 52 weeks, with a 50-day moving average of $90.70 and a 200-day moving average of $114.07. The company maintains a current ratio of 1.39 and a quick ratio of 0.84, alongside a debt-to-equity ratio of 64.77.

Recent Earnings

Abbott Laboratories reported a revenue of $45.13 billion, reflecting a growth of 7.8%. The company's net margin stands at 13.9%, with a return on equity of 12.33%. Earnings per share were $3.57. The next earnings report is expected on July 16, 2026.

Dividend

Abbott Laboratories offers an annual dividend rate of $2.52, yielding 2.78%. The payout ratio is 67.23%, indicating a stable dividend policy.

Insider Buying and Selling at Abbott Laboratories

Recent insider activity at Abbott Laboratories included several purchases. Executive Vice President Mary Moreland bought 5,314 shares at an average price of $94.41 on April 28, 2026. Daniel Starks acquired 10,000 shares at $92.65 on April 27, 2026. Other insiders such as Nita Ahuja and Sally Blount also made smaller purchases, further indicating insider confidence.

Analysts Set New Price Targets

On April 20, 2026, Barclays maintained its 'buy' rating for Abbott Laboratories with a price target of $143. Other firms like Piper Sandler and Oppenheimer also maintained 'buy' ratings with price targets of $115. Overall, the consensus among 24 analysts is a 'buy' recommendation with a target mean price of $116.54.

About Abbott Laboratories

Abbott Laboratories, headquartered in Abbott Park, Illinois, is a global healthcare company that develops and sells a wide range of medical devices and health care products. The company operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. With a workforce of 122,000 employees, Abbott provides products ranging from generic pharmaceuticals to nutritional products and medical devices.

Bottom Line

Financial Engines Advisors' decision to cut its stake in Abbott Laboratories by over 21% reflects a strategic portfolio adjustment. Investors continue to watch Abbott's performance closely, given its strong market position in the healthcare sector and its consistent dividend payouts. While 13F filings are backward-looking, they provide valuable insights into institutional investment trends.